Biotech Values

[wallstarb]

It sounds like Sanofi is matching price or atleast making the generic alternative unactrive at it's current price point - atleast for larger HMO's and hospital groups. It will be interesting to see how much sales is actually affected from this. Possible revised gross sales lower atleast due to the pricing issue.